Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/10/2019
SIETES contiene 92822 citas

 
 
 1 a 20 de 93 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]
2. Cita con resumen
3. Cita con resumen
Murad MH, Montori VM. Synthesizing evidence: shifting the focus from individual studies to the body of evidence. JAMA 2013;309:2217-8. [Ref.ID 95591]
4.Tiene citas relacionadas Cita con resumen
Ioannidis JPA. Mega-trials for blockbusters. JAMA 2013;309:239-40. [Ref.ID 94781]
5.Tiene citas relacionadas Cita con resumen
O'Connor C, Fiuzat M. Antidepressant use, depression, and poor cardiovascular outcomes. The chicken or the egg?. Arch Intern Med 2009;169:2140-1. [Ref.ID 87418]
7. Cita con resumen
Bland JM. The tyranny of power: is there a better way to calculate the sample size?. BMJ 2009;339:1133-5. [Ref.ID 87077]
8.Tiene citas relacionadas Cita con resumen
Kastelein JJP, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009;361:2180-3. [Ref.ID 87072]
9. Cita con resumen
Araya Alpízar C, Galindo Villardon MP. Tamaño de la muestra en investigación clínica. Med Clin (Barc) 2009;133:26-30. [Ref.ID 86075]
10. Cita con resumen
Anónimo. Understanding statistical terms: 1. Drug Ther Bull 2009;47:22-4. [Ref.ID 85346]
11.Tiene citas relacionadas Cita con resumen
Shen L, Kendall DM, Buse JB, Burns C, Taylor KL. Exenatide for type 2 diabetes. Authors' reply. Lancet 2009;373:122-3. [Ref.ID 85004]
12.Tiene citas relacionadas Cita con resumen
Garattini S, Bertele V, Floriani I, Torri V. Exenatide for type 2 diabetes. Lancet 2009;373:122. [Ref.ID 85003]
13. Cita con resumen
Chan-AW, Hróbjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ 2008;337:1404-7. [Ref.ID 84756]
14.Tiene citas relacionadas Cita con resumen
Bertelé V, Angelici L, Barlera S, Garattini S. Thrombolysis or nothing for acute myocardial infarction? It's all the same!. Br J Clin Pharmacol 2008;65:955-8. [Ref.ID 83573]
15.Tiene citas relacionadas Cita con resumen
Ritter JM. Drug regulation & therapeutic efficacy. Br J Clin Pharmacol 2008;65:801-2. [Ref.ID 83109]
16. Cita con resumen
Cooper AJP, Lettis S, Chapman CL, Evans SJW, Waller PC, Shakir S, Payvandi N, Murray AB. Developing tools for the safety specification in risk management plans: lessons learned from a pilot project. Pharmacoepidemiol Drug Saf 2008;17:45-454. [Ref.ID 82982]
17. Cita con resumen
Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, Andrew T, Falchi M, Gwilliam R, Ahmadi KR, Valdes AM, Arp P, Whittaker P, Verlaan DJ, Jhamai M, Kumandari V, Moorhouse M, van Meurs JB, Hofman A, Pols HAP, Hart D, Zhai G, Kato BS, Mullin BH, Zhang F, Deloukast P, Uitterlinden AG, Spector TD. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008;371:1505-12. [Ref.ID 82800]
18. Cita con resumen
Avorn J. In defense of pharmacoepidemiology - embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-21. [Ref.ID 81710]
19.Tiene citas relacionadas Cita con resumen
von Elm E, Altman DG, Pocock SJ, Gotzsche PC, Vandenbroucke JP, for the STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8. [Ref.ID 81325]
20.Tiene citas relacionadas Cita con resumen
Norrie J. Trials of venous thromboembolism prevention. Lancet 2007;370:915-7. [Ref.ID 81073]
Seleccionar todas
 
 1 a 20 de 93 siguiente >>